Nektar repurchases 8.28M shares from BMS for $3M; reduces outstanding shares by 4.34%

NEKTAR THERAPEUTICS

Purchased 8,284,600 BMS-held restricted shares for $3,000,000 aggregate.
Stock repurchase reduces outstanding shares by ~4.34% based on Nov 2023 10-Q count.
2018 Share Purchase Agreement and Investor Agreement with BMS terminated.
Reduction reflected in weighted-average shares for quarter ending June 30, 2024.

item 1.02 item 1.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEKTAR THERAPEUTICS terminated share purchase agreement with Bristol-Myers Squibb Company (effective 2024-02-12).

Action: termination
Agreement: equity purchase
Counterparty: Bristol-Myers Squibb Company
Effective: 2024-02-12

Exact text from the filing

Nektar entered into a privately negotiated Stock Repurchase Agreement with BMS pursuant to which, among other things, Nektar purchased from BMS all of the BMS Nektar Shares (the “Stock Repurchase”) for an aggregate purchase price of $3,000,000 and all rights and obligations of the parties under the Purchase Agreement and the IA were terminated.

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-24-014968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.